Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Drug for Dust Mite Allergy Approved by FDA

XTALKS VITALS NEWS

Dust Mite

Dust mites are microscopic insects which are commonly found in soft furnishings – like carpets, bedding and other furniture – in the home.

Share this!

March 3, 2017 | by Sarah Hand, M.Sc.

Good news for house dust mite allergy sufferers: the FDA has approved Merck, Sharp & Dohme Corp.’s Odactra to treat allergic rhinitis and conjunctivitis in patients between the ages of 18 and 65. The allergen extract is the first of its kind to be administered sublingually.

“House dust mite allergic disease can negatively impact a person's quality of life,” said Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. “The approval of Odactra provides patients an alternative treatment to allergy shots to help address their symptoms.”

Dust mites are microscopic insects which are commonly found in soft furnishings – like carpets, bedding and other furniture – in the home. Symptoms of a dust mite allergy include a runny nose, cough, nasal congestion and watery eyes.



Odactra uses allergen immunotherapy to expose patients to dust mite allergens. By introducing a small amount of these allergens to the immune system on a regular basis, the hope is that the symptoms of the allergy will gradually be reduced.

The drug is taken once-per-day in a dissolvable pill placed under the tongue. Patients take their first dose of Odactra in the presence of a physician in the event that the drug triggers any adverse reactions. Eight to 14 weeks of daily dosing may be necessary before a patient begins to see an improvement in their allergy symptoms.

Multiple clinical trials involving approximately 2,500 participants in Canada, the US and Europe were conducted to assess the safety and efficacy of Odactra. In these trials, patients taking Odactra saw a 16 to 18 percent reduction in their allergy systems and the need to take antihistamines, compared to patients given a placebo.

As a condition of the approval, the FDA is requiring that the drug carry a boxed warning to alert prescribing physicians and patients to the risk of serious, potentially-fatal, allergic reactions. The FDA also requires the patients taking Odactra be prescribed an epinephrine auto-injector in case of adverse reactions.


Keywords: Allergy, FDA, Drug Delivery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.